About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, May 22nd, 2014

The QualityStocks
Daily Stock List


Titan Pharmaceuticals, Inc. (TTNP)

SmarTrend Newsletters reported recently on Titan Pharmaceuticals, Inc. (TTNP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Titan Pharmaceuticals, Inc. is a biopharmaceutical entity developing proprietary therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company’s principal asset is Probuphine®. This product is the first slow-release implant formulation of buprenorphine hydrochloride (buprenorphine). Probuphine® is the first product to utilize ProNeura™ - a novel, proprietary, long-term drug delivery technology. Titan Pharmaceuticals is headquartered in South San Francisco, California. The Company lists on the OTC Bulletin Board.

The Probuphine New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in October 2012 - seeking approval for the treatment of opioid dependence. Titan Pharmaceuticals’ goal is to enter into one or more collaborations with capable pharmaceutical companies to commercialize Probuphine® in the U.S. and worldwide markets, and to develop, potentially, the product for the treatment of chronic pain.

The ProNeura™ technology has the potential to be used in developing products for the treatment of other chronic conditions, including Parkinson's disease. The design of Probuphine® is to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. A seven-day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011. Probuphine® is an investigational subdermal implant for the maintenance treatment of opioid dependence in adult patients. 

The Company is also entitled to royalty revenue of 8-10 percent of net sales of Fanapt® (iloperidone). This is an atypical antipsychotic compound being marketed in the U.S. for the treatment of schizophrenia by Novartis Pharma AG under a sub-license agreement based on a licensed U.S. patent that expires in October 2016 (does not include a possible six month pediatric extension).

At the end of April, Titan Pharmaceuticals announced that the FDA has provided clear guidance on the full clinical study protocol of Probuphine®. The study was submitted for FDA review in mid-March by Titan's partner, Braeburn Pharmaceuticals. The expectation is that the study will commence enrollment by mid-year. Study completion is anticipated by the middle of 2015.

Titan Pharmaceuticals, Inc. (TTNP), closed Thursday's trading session at $0.63, down 0.16%, on 29,289 volume with 17 trades. The average volume for the last 60 days is 159,620 and the stock's 52-week low/high is $0.4401/$1.27.

Sunvalley Solar, Inc. (SSOL)

Wallstreetlivechat, Fast Moving Stocks, The Stock Scout, PennyStockClub, PennyStocks24, Penny Stock Rumble, and Penny Stock Pros reported previously on Sunvalley Solar, Inc. (SSOL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed Sunvalley Solar, Inc. is a solar power technology and system integration enterprise. The Company offers comprehensive solar energy technology, system design, installation, equipments, and technical support for electrical contractors, builders, homeowners, government entities, and businesses/commercial buildings. It provides an all-in-one service for customers' solar system needs. This is from system design and permitting, to installation and final inspection. Sunvalley Solar has its corporate office in Los Angeles, California.

The Company is a leading solar electric equipment wholesale distributor for solar photovoltaic equipment of manufacturers.  Sunvalley Solar specializes in packaged solar system solutions. Its focus is Solar System Design and Installation, Solar Equipment Distribution, Solar Technology Research and Development, and as a National Solar Technical Support and Service Center. Sunvalley Solar’s Research and Development (R&D) team consists of PhDs in Optoelectronics. The team specializes in photovoltaic panel technologies (coating and focusing).

Sunvalley Solar’s growth strategy includes developing and commercializing its proprietary solar technologies. This includes its coating and focusing technologies, racking, and panel cleaning system. In addition, the Company’s growth strategy includes promoting and enhancing its brand and reputation in solar design and integration and expanding its installation business, and developing a PV panel manufacturing capability to provide high efficiency and low cost solar panels to the U.S. market. Furthermore, its focus is getting involved in the private power providing business (Distributed Power Plants).

The Company’s R&D team engages in advanced solar technologies research, development, and commercialization. Sunvalley Solar’s experience includes residential, small commercial, and complex large commercial solar system integration projects. Its projects include 975 kW commercial solar power systems for distribution warehouses and manufacturing companies, and 1 MW commercial solar power systems for agriculture farms and cold storage facilities.

Last month, Sunvalley Solar announced that it was awarded a new 1,122KW solar system installation contract from Wreden Ranch in Handord, California. The contract is for a system able to generate 2,096,352Wh of electrical power each year. The system uses 3,740 pieces of high-efficiency 300-watt poly-crystalline solar panels.

Sunvalley Solar, Inc. (SSOL), closed Thursday's trading session at $0.0195, down 1.52%, on 160,392 volume with 15 trades. The average volume for the last 60 days is 463,660 and the stock's 52-week low/high is $0.007/$0.041.

XcelMobility, Inc. (XCLL)

Greenbackers, PennyStocks24, Penny Stock Rumble, and Pennybuster reported earlier on XcelMobility, Inc. (XCLL), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.

Based in Redwood City, California, XcelMobility, Inc. is a leading developer of mobile internet products and services. The Company is combining wearable computing devices, location based technologies, and cloud computing to become a leading developer of mobile internet products and services. It is concentrating specifically on China's growing mobile market of well over 1 billion users.  XcelMobility’s shares trade on the OTC Markets’ OTCQB.

XcelMobility has two divisions: the Wearable Computing Group and the Video and Security Group. The Wearable Computing Group develops and markets world leading cloud connected wearable computing solutions. These solutions combine advanced sensors, wearable computing, location based applications and an always connected national cloud based network. This group targets large and lucrative monitoring applications in private and public markets. 

The Video and Security Group delivers location and video enhanced security systems for public and private security forces in China. It is building next generation security and surveillance systems. These systems combine wearable computing, location based services and cloud based advanced video solutions for security force tracking and surveillance.

In January of this year, XcelMobility announced its Companion Solution. This is the first "always on" cloud-connected smartwatch system with software applications specifically focused on monitoring loved ones and private/public security forces. The Companion Solution expands the market opportunity for XcelMobility’s innovative smartwatch through incorporating a complete cloud-connected system enabling the smartwatch to always be connected to the Company’s national cloud computer network offering 24/7 services to the user. 

Recently, XcelMobility announced the financial results of its 2013 fiscal year ending December 31, 2013. Revenue for the year ended December 31, 2013 was $2,781,745. This represents an increase of $2,504,339 or 902.8 percent from $277,406 for the year ended December 31, 2012. Gross profit for the year ended December 31, 2013 was $2,287,260. This represents an increase of $2,027,807 or 781.6 percent from $259,453 for fiscal 2012. XcelMobility reported a net loss of ($504,848) for the year ended December 31, 2013 versus a net loss of ($434,769) for the year ended December 31, 2012.

XcelMobility, Inc. (XCLL), closed Thursday's trading session at $0.0628, down 10.29%, on 77,600 volume with 7 trades. The average volume for the last 60 days is 64,586 and the stock's 52-week low/high is $0.025/$0.177.

Mass Megawatts Wind Power, Inc. (MMMW)

RedChip reported recently on Mass Megawatts Wind Power, Inc. (MMMW), PennyStocks24 did earlier, and today we report on the Company, here at the QualityStocks Daily Newsletter.

Headquartered in Worcester, Massachusetts, Mass Megawatts Wind Power, Inc. is a leader in the development of low-cost, clean energy systems. The design of these is to meet the increasing worldwide demand for energy through the use of environmentally-friendly technologies. This includes patented innovations for solar power systems, which provide an economical option for commercial and residential users interested in green energy applications. The Company’s intention is to build over 1000 megawatts over the next six years. As the units are built, they will be placed immediately into service. Mass Megawatts Wind Power lists on the OTC Markets’ OTCQB.

The Company offers an assortment of low-cost, high-efficiency, solar power solutions. These are suited for business and residential locations. The design of each system is for durable, long-term, maintenance-free operation, with scalable capacity to meet the energy needs of residential, small commercial, as well as large commercial customers. Mass Megawatts offers affordable, renewable-energy plans to residential and commercial electricity users in a number of states. These include New York, Massachusetts, Connecticut, Maryland, New Jersey, Pennsylvania, Delaware, and Illinois. 

The Company has entered into the $12 billion U.S. solar power market. It has done so with the development of a new solar tracking technology. This technology significantly increases the level of energy produced by solar power systems. The patent pending Mass Megawatts 'Solar Tracking System' (STS) is a complete solar power system. The design of it is to continually adjust the position of solar panels to receive the optimal level of direct sunlight throughout the day. The Mass Megawatts STS utilizes a low-cost structure that adds stability to the overall system while improving solar energy production by 22 to 28 percent.

Today, Mass Megawatts Wind Power announced that Worcester, Massachusetts would be the location of its first Community Solar project. This project will allow residents and businesses to directly invest in solar power. With this plan, the Company would develop and maintain solar power systems that investors can secure ownership in with the purchase of shares in 1 kW increments. The value of all solar power generation, including tax incentives, would be credited to the investors in proportion to their investment.

Mass Megawatts Wind Power, Inc. (MMMW), closed Thursday's trading session at $0.02, up 11.11%, on 72,952 volume with 11 trades. The average volume for the last 60 days is 225,183 and the stock's 52-week low/high is $0.015/$0.08.

Skyline Medical, Inc. (SKLN)

Information Solutions Group, Greenbackers, Wallstreetlivechat, Buzz Stocks, Planet Penny Stocks, Penny Pick Finders, and PennyStockProphet, reported earlier on Skyline Medical, Inc. (SKLN), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Founded in 2002, OTCQB-listed Skyline Medical, Inc. has a fully automated, patented, Food and Drug Administration (FDA) cleared, surgical fluid disposal system. This system essentially eliminates certain operating room workers' exposure to blood, irrigation fluid, and other potentially infectious fluids found in the surgical environment. The Company formerly went by the name BioDrain Medical, Inc. It changed its name to Skyline Medical, Inc. in August 2013. Skyline Medical has its headquarters in Eagan, Minnesota.

The Company’s STREAMWAY® System fully automates the collection, measurement, and disposal of surgical fluids. The design of this system is to result in reducing overhead costs to hospitals and surgical centers, improve Occupational State and Health Association (OSHA) and other regulatory compliance agencies' safety concerns, and streamline the efficiency and reduce the operating costs of the operating room. The STREAMWAY® System is eco-friendly.

The system contributes to cleaning up the environment. Presently, roughly 50 million bloody, potentially disease infected canisters go to landfills each year in the U.S. The number of canisters can be substantially reduced with the installation of the STREAMWAY® System. With the STREAMWAY® System, operative fluid is suctioned directly from the surgical field into the system. It automatically measures and records volume before it disposes of the fluid directly into a facility’s existing plumbing system. Cleaning the STREAMWAY® System involves detaching the procedure filter, connecting the Company’s proprietary cleaning solution, and activating the cleaning cycle on the touch screen.

In November 2013, Skyline Medical announced that it made innovative enhancements of its flagship STREAMWAY® System product. The design of the enhanced version of the STREAMWAY® System is to be even more intuitive. This includes a colored touchscreen, step by step menu controls, an easy-to-navigate digital color operator control panel and back-ups for additional storage. The unit will feature a simplified cleaning process and a smaller footprint where it is installed. All of this will help personnel streamline the fluid waste disposal process in a safe, efficient manner.

For the first quarter ended March 31, 2014, Skyline Medical shipped three enhanced STREAMWAY® units. The Company sold and shipped eight STREAMWAY® units in April. Moreover, 22 STREAMWAY® trials have been scheduled through the first week in June, with one already in place.

Skyline Medical, Inc. (SKLN), closed Thursday's trading session at $0.135, down 6.90%, on 30,276 volume with 7 trades. The average volume for the last 60 days is 186,930 and the stock's 52-week low/high is $0.106/$0.47.


The QualityStocks
Company Corner


VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.67, even for the day, on 9,000 volume with 3 trades. The stock’s average daily volume over the past 60 days is 4,865, and its 52-week low/high is $0.25/$0.89.

VistaGen Therapeutics Inc. today announced that it has become a member of the Cardiac Safety Technical Committee, Cardiac Stem Cell Working Group, and Proarrhythmia Working Group of the Health and Environmental Sciences Institute (HESI), a global branch of the International Life Sciences Institute (ILSI), whose members include most of the world's largest pharmaceutical and biotechnology companies. Using mature cardiomyocytes (heart cells) differentiated from human pluripotent stem cells, VistaGen developed its CardioSafe 3D™ bioassay system to predict the in vivo cardiac effects, both toxic and non-toxic, of small molecule drug candidates with greater speed and precision than the long-established, surrogate safety models most often used in drug development.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve.  According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months.  VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits.  In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations. 

AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data.  To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Joins HESI's Cardiac Safety Committee and Working Groups

VistaGen Receives Notice of Allowance for U.S. Patent Expanding Stem Cell Technology Platform for Drug Rescue and Regenerative Medicine

VistaGen Joins the Cardiac Safety Research Consortium

Zenosense, Inc. (ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.46, up 6.98%, on 50,517 volume with 37 trades. The stock’s average daily volume over the past 60 days is 17,424, and its 52-week low/high is $0.284/$1.00.

Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.

Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.

The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.

Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.

Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer

Zenosense, Inc. Company Blog

Zenosense, Inc. News:

Zenosense, Inc. Provides Development Update

Zenosense, Inc. Extends License to Include Cancer Applications

Zenosense, Inc. Enters Into $475,000 Securities Purchase Agreement

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.15, up 25.00%, on 30,400 volume with 8 trades. The stock’s average daily volume over the past 60 days is 59,428, and its 52-week low/high is $0.03/$0.41.

Global Payout, Inc. (GOHE) specializes in customized payment solutions for businesses and organizations worldwide. The company’s global network of banks and processing partners enable companies and organizations to efficiently deploy a customized payment solution configured specifically for each client. From solving a single payment issue to meeting an entire global payment requirement, Global Payout in conjunction with its partners delivers modular payment solutions.

Global Payout has a product line of prepaid "off the shelf" products that can be utilized or Global Payout can customize payment solutions for qualified businesses. By coupling its network of international banks and third-party processing relationships with an innovative payment platform, Global Payout enables organizations to "plug into" an efficient and cost effective method of paying employees, contractors, investors, and commissioned agents wherever they might be located in the world.

Global Payout began operations as a business to business provider of pre-paid debit cards for payroll and general spend programs. The company then launched a Prepaid Discover® card to meet the demand of its business clients in the United States. As a result of these efforts and with the input of their client base, Global Payout then greatly extended its reach by developing a new proprietary “payment platform” which enables companies and organizations to make necessary payments in every country a company does business. Clients can now make international payments without the need to establish banking relationships in each and every country they do business. Businesses now have an efficient, compliant and simplified system to make their all necessary international payments using Global Payout’s proprietary payment platform.

Global Payout delivers dependable and secure global payment solutions for companies worldwide. This relieves clients of burdensome and time consuming efforts to establish banking relationships everywhere they do business. The company’s “consolidated payment gateway” product can be configured specifically to the needs of each client within a short period of time. Global Payout is led by a management team comprised of pioneers in domestic and international payment delivery solutions. The company is well positioned to leverage their long standing international financial relationships to expand their services and global reach. Even during this expansion, Global Payout remains committed to serving domestic and international clients and providing them with customized one-stop solutions that address each client’s specific payment needs. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

Chip and PIN Prepaid MasterCard® Now Available Internationally

Gateway To 2.5 Billion Under-Banked Adults Rapidly Expanding

Global Payout Wins New Contract To Provide Recurring Payroll Disbursements

Mabwe Minerals Inc. (MBMI)

The QualityStocks Daily Newsletter would like to spotlight Mabwe Minerals Inc. (MBMI). Today, Mabwe Minerals Inc. closed trading at $0.06, up 20.00%, on 2,000 volume with 3 trades. The stock’s average daily volume over the past 60 days is 29,204, and its 52-week low/high is $0.03/$0.70.

Mabwe Minerals Inc. (MBMI) is a U.S. based natural resources and hard asset company focused on the mining, logistics, and commercial sales of industrial minerals and metals, with a particular emphasis on barite. The company's operations are conducted through its Zimbabwe affiliate, Mabwe Mineral Zimbabwe (Private) Ltd. Transitioning into commercial production, MBMI's company fundamentals are well positioned with virtually no debt and key strategic partnerships in place.

Along with its affiliate, Mabwe Minerals Zimbabwe (Private) Ltd., an indigenous Zimbabwe company, the company owns 100% of the mineral & metal rights to Dodge Mine. The mine will be managed by the company's minority owned partner, WGB Kinsey & Company, Zimbabwe's most experienced mining & construction company representing four generations of Kinsey leadership. Management believes WGB Kinsey & Company has all the necessary equipment and management experience to efficiently perform all the mining operations at Dodge Mine.

The Dodge Mine property consists of three hydrothermal mountains representing 123 hectares containing multiple deposits of superior-grade barite, limestone, and talc. Hydrothermal barite deposits throughout Dodge Mine represent the highest grade of new barite sources to be brought into commercial production in years. A third party oil & gas drilling sector geologist recently confirmed that the multiple barite deposits are considered "World Class" in quality and highly efficient to mine via open pit extraction following the barite veins and salvaging large percentages of barite within the halo zones via jigging systems.

With a continuing worldwide shortage of high-grade barite, Mabwe Minerals is in the right place at the right time. The company's current customer uses barite as a weighting agent in oil & gas drilling applications in the Gulf of Mexico, home to the largest concentration of active rigs in the world. Coupled with the recent massive discovery of oil & gas off the coast of neighboring Mozambique along with new drilling contracts expected in the region, MBMI is in an attractive geographical location to capture the expected demands of this emerging market. Moving from an exploration stage company into commercial barite production, Mabwe Minerals is well positioned to generate significant shareholder returns. Disclaimer

Mabwe Minerals Inc. Company Blog

Mabwe Minerals Inc. News:

Raptor Resources Holdings Issues Update on the Derbyshire Stone Quarry

Raptor Resources Holdings Acquires the Derbyshire Stone Quarry

Raptor Resources Holdings Completes Expansion of the Dodge Mine Mountain Range

Start Scientific, Inc. (STSC)

The QualityStocks Daily Newsletter would like to spotlight Start Scientific, Inc. (STSC). Today, Start Scientific, Inc. closed trading at $0.56, even for the day. The stock’s average daily volume over the past 60 days is 8,692, and its 52-week low/high is $0.09/$2.00.

Start Scientific, Inc. (STSC) is an oil extraction company backed by highly experienced leadership with strong industry knowledge to identify and acquire low-risk land lease opportunities on properties with known oil deposits, develop facilities on these properties to cost effectively extract the oil, and then distribute the refined oil for sale onto the open market.

With leases or contracts to acquire leases in Texas, Mississippi and Romania already in place, the company is also negotiating several projects in North Dakota and New Mexico. The initial objective is to take advantage of low-risk producing, exploration and development oil and gas opportunities that are too small for the mid-sized oil and gas companies.

Founder Norris R. Harris contributes broad experience in oilfield property acquisitions and enhanced field production management, and has established an extensive base of contacts in the oil and gas industry to provide invaluable expertise for Start Scientific to evaluate and exploit its existing oil and gas properties and to seek other opportunities in the oil and gas industry.

Start Scientific’s management and staff collectively retain more than 65 years of experience in drilling, extraction, delivery and management of natural resource companies. In addition to leveraging the expertise of its highly qualified staff, the company seeks out partnerships and joint ventures to accelerate growth and become an increasingly vital part of the ever expanding oil industry. Disclaimer

Start Scientific, Inc. Company Blog

Start Scientific, Inc. News:

Start Scientific, Inc. (STSC) – Exploring and Developing Oil and Gas Assets

Start Scientific, Inc. (STSC) is “One to Watch”


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Real Pennies





By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251